Lomefloxacin


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Acute bacterial exacerbation of chronic bronchitis
Adult: 400 mg once daily for 10 days.
Renal impairment: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.
CrCl (ml/min)Dosage Recommendation
10-40 Initially, 400 mg daily. Maintenance: 200 mg daily.


Oral
Prophylaxis of surgical infections
Adult: 400 mg as a single dose 1-6 hr before procedure.

Oral
Uncomplicated urinary tract infections
Adult: 400 mg once daily. Due to E. coli: For 3 successive days. Due to K. pneumoniae, P. mirabilis or S. saprophyticus: For 10 successive days.
Renal impairment: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.
CrCl (ml/min)Dosage Recommendation
10-40Initially, 400 mg daily. Maintenance: 200 mg daily.


Oral
Complicated urinary tract infections
Adult: Due to E. coli, K. pneumoniae, P. mirabilis or P. aeruginosa: 400 mg once daily for 14 successive days.
Renal impairment: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.
CrCl (ml/min)Dosage Recommendation
10-40Initially, 400 mg daily. Maintenance: 200 mg daily.


Ophthalmic
Bacterial conjunctivitis
Adult: Instil 0.3% solution into the affected eye/s.

Otic/Aural
Otitis externa
Adult: Instil 0.3% solution into the affected ear/s.

Otic/Aural
Otitis media
Adult: Instil 0.3% solution into the affected ear/s.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to the drug or other quinolones; children <18 yr; pregnancy and lactation.
Special Precautions
Avoid prolonged exposure to sunlight or artificial UV light. Known or suspected CNS disorders e.g. severe cerebral arteriosclerosis, epilepsy or other factors that predispose to seizures. Avoid in patients with known QT prolongation, uncorrected hypokalaemia. May impair ability to drive or operate machinery. Renal impairment.
Adverse Reactions
Nausea, abdominal pain or discomfort, diarrhoea; headache, dizziness, insomnia; rash, pruritus, photosensitivity; thrombocytopenia.
Potentially Fatal: Anaphylactic or anaphylactoid reactions.
Overdosage
Empty the stomach by inducing vomiting or by gastric lavage. Treatment is supportive. Maintain adequate hydration. Haemodialysis or peritoneal dialysis is unlikely to be helpful.
Drug Interactions
Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.
Potentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.
Action
Lomefloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
Absorption: Rapid and complete from the GI tract (oral); peak plasma concentrations after 1-1.5 hr. Absorption delayed with food.
Distribution: Widely distributed; lungs and prostate. Protein-binding: 10%.
Excretion: Via urine (as unchanged drug and small amounts of glucuronide metabolites); may be prolonged in renal impairment. Via faeces (small amounts as unchanged drug); 7-8 hr (elimination half-life).
CIMS Class
Ear Anti-Infectives & Antiseptics / Eye Anti-Infectives & Antiseptics / Quinolones
ATC Classification
J01MA07 - lomefloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
S01AE04 - lomefloxacin ; Belongs to the class of quinolone antiinfectives. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on lomefloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in